Therapeutic Response

PD-L1 >= 1% status confers therapeutic sensitivity to Fluorouracil in combination with Nivolumab and Oxaliplatin in patients with Esophageal Squamous Cell Carcinoma.

Statements

Source and description
Opdivo (nivolumab) [product monograph]. HC. Health Canada approved nivolumab, in combination with fluoropyrimidine- and platinum-containing chemotherapy, for the treatment of adult patients with unresectable or metastatic ESCC, with tumour cell PD-L1 expression >= 1% as determined by a validated test, and no prior systemic therapy for metastatic ESCC.